Skip to main content


Fig. 3 | Molecular Cancer

Fig. 3

From: Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts

Fig. 3

Antitumor activity of the combination of PTX, bevacizumab and MEK162 in MNHOC239 PDX model. Xenograft MNHOC239 was transplanted subcutaneously and when tumor masses reached 100-150mg, mice were randomized to receive vehicle (-♦-), or treated with Bevacizumab and MEK162 (-■-), paclitaxel and MEK162 (-▲-), paclitaxel and bevacizumab (--), or paclitaxel and bevacizumab and MEK162 (-x-). Data are the mean ± SE of tumor masses, as described in Materials and Methods; each group consisted of 8-10

Back to article page